English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Breast cancer is one of the most frequent and aggressive primary tumors among women of all races. Matrix metalloproteinase (MMPs), a family of zinc- and calcium-dependent secreted or membrane anchored endopeptidases, is overexpressed in varieties of diseases including breast cancer. Therefore, noninvasive visualization and quantification of MMP  in vivo  are of great interest in basic research and clinical application for breast cancer early diagnosis. Herein, we developed a  99m Tc labeled membrane type I matrix metalloproteinase (MT1-MMP) specific binding peptide, [ 99m Tc]-(HYNIC-AF7p)(tricine)(TPPTS), for  in vivo  detection of MDA-MB-231 breast tumor by single photon emission computed tomography (SPECT). [ 99m Tc]-(HYNIC-AF7p)(tricine)(TPPTS) demonstrated nice biostability and high MT1-MMP binding affinity  in vitro  and  in vivo . Tumor-to-muscle ratio was found to reach to the highest (4.17±0.49) at 2 hour after intravenously administration of [ 99m Tc]-(HYNIC-AF7P)(tricine)(TPPTS) into MDA-MB-231 tumor bearing mice. Overall, [ 99m Tc]-(HYNIC-AF7P)(tricine)(TPPTS) demonstrated great potential for MT1-MMP targeted detection  in vivo  and it would be a promising molecular imaging probe that are probably beneficial to breast cancer early diagnoses.

Development of a Radiolabeled Peptide-Based Probe Targeting MT1-MMP for Breast Cancer Detection